Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.

World journal of gastroenterology - 14 Sept 2013

Sato Ken, Yanagisawa Masatoshi, Hashizume Hiroaki, Yamazaki Yuichi, Horiguchi Norio, Kakizaki Satoru, Mori Masatomo

Abstract excerpt

We devised an extended 72-wk peginterferon-α-2a/ribavirin therapy regimen for the retreatment of highly intractable cases, i.e., 48-wk peginterferon-α-2b/ribavirin therapy-intractable cases. Although 2 cases achieved a rapid virological response to 72-wk peginterferon-α-2a/ribavirin therapy, 1 case failed to achieve a sustained virological response. Although the reason for this difference in the effectiveness of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 24039372
DOI: 10.3748/wjg.v19.i34.5754
PMCID: PMC3769916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2.PMID 24039372Read ↗

What is the optimal duration of therapy in patients with hepatitis C genotype 2 or 3 infection?: a review.Semantic proximity Read ↗

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.Semantic proximity Read ↗

Effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis.Semantic proximity Read ↗

Chronic hepatitis C therapy: changing the rules of duration.Semantic proximity Read ↗

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.Semantic proximity Read ↗

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.Semantic proximity Read ↗

[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].Semantic proximity Read ↗

Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.Semantic proximity Read ↗

Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a.Semantic proximity Read ↗

New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.Semantic proximity Read ↗

Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.